Leadership


  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    eranicle via Getty Images
    Image attribution tooltip
    Q&A

    How AZ’s respiratory wins are ramping up for a bigger prize in COPD

    As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.

    By Oct. 29, 2024
  • Biotech pathfinders, PharmaVoice 100
    Image attribution tooltip
    Permission granted by Photo illustration: Industry Dive; Getty Images
    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Biotech Pathfinders

    Leaders solving biology's toughest puzzles and driving innovation forward.

    By Oct. 23, 2024
  • drug shopping cart Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    George Clerk via Getty Images
    Image attribution tooltip

    With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble

    Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.

    By Oct. 22, 2024
  • Hands clasping
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Patient Champions

    Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.

    By Oct. 22, 2024
  • heart monitor chart
    Image attribution tooltip
    PharmaVoice/PharmaVoice
    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Cardiometabolic All-Stars

    Leaders tackling long-standing health needs with new solutions.

    By Oct. 18, 2024
  • Peyton Howell horizontal shot
    Image attribution tooltip
    Permission granted by Parexel
    Image attribution tooltip

    Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with

    From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.

    By Oct. 18, 2024
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    Want to launch a blockbuster? An AstraZeneca exec breaks it down.

    Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.

    By Alexandra Pecci • Oct. 16, 2024
  • PharmaVoice 100 trailblazers
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Trailblazers

    Industry leaders charting new paths in science and business. 

    By Oct. 16, 2024
  • Microscope blood slide
    Image attribution tooltip
    Motortion via Getty Images
    Image attribution tooltip

    Regeneron takes the long-haul approach to oncology, stumbles and all

    Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.

    By Oct. 10, 2024
  • Joe Panetta
    Image attribution tooltip
    Permission granted by Biocom
    Image attribution tooltip
    Q&A

    California is a life sciences leader. Joe Panetta has been one of its most vocal advocates.

    The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.

    By Alexandra Pecci • Oct. 1, 2024
  • studying brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades

    The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.

    By Kelly Bilodeau • Sept. 26, 2024
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip
    Q&A

    Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters

    Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.

    By Sept. 26, 2024
  • Alicia Zhou, CEO, Cancer Research Institute
    Image attribution tooltip
    Permission granted by CRI
    Image attribution tooltip
    Q&A // First 90 Days

    Want better cancer treatments? Make biopharma more like Silicon Valley

    Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.

    By Sept. 24, 2024
  • Scientist suit handshake
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    At J&J, oncology R&D meets commercial strategy in a quest for new standards of care

    The disparate teams of research and commercial at J&J work closely together from the get-go.

    By Sept. 19, 2024
  • Lilly Biotechnology Center in San Diego, California
    Image attribution tooltip
    Michael Vi / Getty Images via Getty Images
    Image attribution tooltip
    Q&A

    How Lilly’s sustainability goals come face to face with massive growth

    Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.

    By Sept. 12, 2024
  • Cristal Downing, chief communications and public affairs officer, executive vice president, Merck & Co.
    Image attribution tooltip
    Permission granted by Merck & Co.
    Image attribution tooltip

    Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that.

    Cristal Downing is helping Merck & Co. buck pharma’s zipped-lip status quo and usher in a “new era” of openness, transparency and “overt communication.”

    By Alexandra Pecci • Sept. 5, 2024
  • Wall Street buildings
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Their Alzheimer’s treatment worked — but shares fell anyway

    Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.

    By Aug. 29, 2024
  • Dr. PK Morrow headshot
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip
    Q&A // First 90 Days

    With a new oncology R&D head, Takeda revamps its strategy

    The company is using a “three-by-four” approach to sharpen its cancer R&D aims.

    By Alexandra Pecci • Aug. 27, 2024
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin taps Amgen, Roche vets in executive reshuffle

    Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.

    By Jacob Bell • Aug. 22, 2024
  • Dr. Reed Tuckson, founder, Black Coalition Against COVID
    Image attribution tooltip
    Permission granted by Reed Tuckson
    Image attribution tooltip

    Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through

    A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.

    By Aug. 15, 2024
  • Brain scan pen blood vessel
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients

    A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.

    By Aug. 13, 2024
  • Eli Lilly CEO Dave Ricks Speaks At The Economic Club Of New York
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Pharma execs react to final drug price negotiations with Medicare

    Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.

    By Aug. 9, 2024
  • James Wilson of the University of Pennsylvania
    Image attribution tooltip
    Permission granted by University of Pennsylvania
    Image attribution tooltip

    Jim Wilson, prominent gene therapy researcher, to depart UPenn

    Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.

    By Ned Pagliarulo • Aug. 5, 2024
  • Robot hand
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    What pharma has learned from AI

    As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.

    By Aug. 2, 2024
  • head shaped bookshelf filled with books on black background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Read to lead: 6 books pharma execs swear by

    From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.

    By Alexandra Pecci • Aug. 1, 2024